Last reviewed · How we verify
DWC202405, DWC202314
DWC202405 and DWC202314 are both botulinum toxin type A serotypes.
DWC202405 and DWC202314 are both botulinum toxin type A serotypes. Used for Chronic sialorrhea, Upper limb spasticity.
At a glance
| Generic name | DWC202405, DWC202314 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | Botulinum toxin |
| Target | Acetylcholine release inhibitor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
They work by inhibiting the release of acetylcholine at the neuromuscular junction, resulting in muscle relaxation and reduced muscle spasms.
Approved indications
- Chronic sialorrhea
- Upper limb spasticity
Common side effects
- Dry mouth
- Headache
- Injection site pain
- Muscle weakness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWC202405, DWC202314 CI brief — competitive landscape report
- DWC202405, DWC202314 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI